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ABSTRACT
Introduction. Actual 5-year survival rates of 10–18%
have been reported for patients with resected pancreatic
adenocarcinoma (PC), but the use of multimodality therapy
was uncommon in these series. We evaluated long-term
survival and patterns of recurrence in patients treated for
PC with contemporary staging and multimodality therapy.
Methods. We analyzed 329 consecutive patients with PC
evaluated between 1990 and 2002 who underwent resec-
tion. Each received a multidisciplinary evaluation and a
standard operative approach. Pre- or postoperative che-
motherapy and/or chemoradiation were routine. Surgical
specimens of 5-year survivors were rereviewed. A multi-
variate model of factors associated with long-term survival
was constructed.
Results. Patients underwent pancreaticoduodenectomy
(n = 302; 92%), distal (n = 20; 6%), or total pancreatec-
tomy (n = 7; 2%). A total of 108 patients (33%) underwent
vascular reconstruction, 301 patients (91%) received
neoadjuvant or adjuvant therapy, 157 specimens (48%)
were node positive, and margins were microscopically
positive in 52 patients (16%). Median overall survival and
disease-specific survival was 23.9 and 26.5 months.
Eighty-eight patients (27%) survived a minimum of
5 years and had a median overall survival of 11 years. Of
these, 21 (24%) experienced recurrence, 7 (8%) after
5 years. Late recurrences occurred most frequently in the
lungs, the latest at 6.7 years. Multivariate analysis identi-
fied disease-negative lymph nodes (P = .02) and no prior
attempt at resection (P = 0.01) as associated with 5-year
survival.
Conclusions. Our 27% actual 5-year survival rate for
patients with resected PC is superior to that previously
reported, and it is influenced by our emphasis on detailed
staging and patient selection, a standardized operative
approach, and routine use of multimodality therapy.
Surgical resection of the involved portion of pancreas
has long been characterized as the only potentially curative
therapy for patients with pancreatic adenocarcinoma (PC).
Although removal of the primary tumor is necessary to
ensure long-term survival, it is usually not sufficient. Of the
10% of patients who seek care with anatomically localized,
stage I and II PC, surgical resection alone has been asso-
ciated with a median survival of only 11–20 months as a
result of high rates of postoperative tumor recurrence.1–5
Such data provide support for ongoing efforts to combine
surgery with systemic therapies and chemoradiation. For
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patients who have locally advanced (stage III) PC, com-
plete resection of the primary tumor is usually not possible,
and for those with metastatic (stage IV) PC, surgery
directed at the primary tumor offers no clinical benefit.
Therein lies the importance of accurately defining the
extent of disease at the time of diagnosis and reserving
surgery for those patients with localized, nonmetastatic PC
who can undergo a complete gross resection of the primary
tumor.6,7
For patients with resectable PC, actual rates of long-
term survival and systematic analyses of clinicopathologic
factors associated with it have only recently been pub-
lished.8–14 Series of long-term survivors published within
the past decade demonstrate that 10–18% of patients who
have undergone resection for PC at major referral centers
have survived at least 5 years. However, most such patients
were treated in an era in which pretreatment staging was
inferior to that available today, the use of adjuvant/neo-
adjuvant therapy was uncommon, and vascular resection
and reconstruction at the time of pancreatectomy was
rarely performed.15 Moreover, these series often included
patients with incompletely resected locally advanced dis-
ease (grossly positive margins of resection, R2) and those
with metastatic disease not appreciated on preoperative
imaging, in whom the postoperative outcome is expected to
be poor.16 Finally, the data presented in these reports were
often incomplete, particularly with regard to the timing and
pattern of disease recurrence. Taken together, these limi-
tations make the conclusions drawn from prior studies of
long-term, postsurgical survival difficult to apply to
patients treated with a more modern and systematic mul-
tidisciplinary approach to their disease.
Over the past two decades, important advances in the
perioperative management of patients with PC have led to a
reduction in the morbidity and mortality associated with
pancreatic surgery. In an attempt to further improve patient
outcome, we and others have sought to better define who
should undergo surgery with a more objective definition of
the term resectable, to extend the limits of pancreatico-
duodenectomy (PD) to include a standardized approach to
venous resection when needed, and to emphasize the rou-
tine use of combined modality therapy.17–19
At our institution, the pretreatment staging evaluation,
treatment, and follow-up of all patients with PC is coor-
dinated by a multidisciplinary working group that meets
weekly and is supported by an integrated database and
tumor bank.20 Since 1990, we have used standardized
definitions and algorithms for clinical/radiographic staging,
surgical technique, and histopathologic analysis of surgical
specimens. Recent outcome data have supported our
approach to venous resection and reconstruction when
necessary to achieve a gross complete (R0, R1) resection.18
Finally, results from our clinical trials of neoadjuvant
therapy followed by surgery has led to an institutional bias
toward this approach for patients with potentially resect-
able (stage I and II) and borderline resectable (subgroup of
stage III) PC; in the absence of neoadjuvant therapy,
postoperative adjuvant therapy has been used whenever
possible.21–27 Therefore, this report reflects a relatively
homogenous population of consecutive patients who have
been accurately staged and treated in a uniform fashion.
The long-term outcomes reported herein accurately repre-
sent the natural history of disease in patients with
resectable pancreatic cancer treated with a multidisciplin-
ary approach.
PATIENTS AND METHODS
All patients who underwent evaluation for presumed or
biopsy-proven PC were treated by members of our multi-
disciplinary pancreatic tumor study group in a disease-site-
specific gastrointestinal outpatient center staffed by surgi-
cal oncologists, medical oncologists, and radiation
oncologists. The treatment algorithm for each patient was
established and coordinated by the multidisciplinary team
at a weekly meeting. All clinical data were prospectively
recorded in a database maintained in the Department of
Surgical Oncology, and corresponding biospecimens were
preserved in an integrated tumor bank.20
Clinical data of all patients who underwent evaluation
for presumed or biopsy-proven PC between March 1990
and September 2002 and who underwent resection of their
primary tumor were reviewed. Patients with a final diag-
nosis of invasive intraductal papillary mucinous neoplasm,
mucinous cystadenocarcinoma, neuroendocrine carcinoma,
or any other nonpancreatic periampullary adenocarcinoma
were specifically excluded from analysis.
Staging
Only patients with tumors initially characterized as
either resectable or borderline resectable were considered
for surgery. Staging was established by using a multide-
tector contrast-enhanced computed tomographic (CT) scan
of the abdomen and was confirmed when necessary by
multidisciplinary review. Resectable pancreatic cancer was
anatomically defined by the following: (1) absence of ex-
trapancreatic disease; (2) no evidence of tumor extension to
the superior mesenteric artery (SMA), celiac axis, or
hepatic artery as defined by the presence of a tissue plane
between the tumor and these arteries; and (3) a patent
superior mesenteric–portal vein (SMPV) confluence.28
Anatomically defined borderline resectable tumors were
those that demonstrated tumor abutment (180 or less of
the circumference of the vessel) of the SMA or celiac axis;
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tumor abutment or encasement ([180 of the circumfer-
ence of the vessel) of a short segment of the hepatic artery;
or short-segment occlusion of the superior mesenteric vein,
portal vein, or SMPV confluence that was amenable to
vascular resection and reconstruction.17,29
Treatment Sequencing
For patients with resectable PC as defined above, we
have had an institutional focus on the development of
clinical trials exploring the use of protocol-based neoad-
juvant therapy before surgical resection.22–24,26,27,30 In
general, patients with resectable, biopsy proven disease
usually received neoadjuvant therapy either on or off pro-
tocol; if tissue confirmation of disease was not obtained,
then a surgery-first strategy was used. Patients who
underwent surgery first, followed by adjuvant chemoradi-
ation and/or systemic chemotherapy, also included those
patients with resectable disease who required an urgent
operation and those patients who chose this treatment
sequence. Although postoperative adjuvant therapy was
favored in these situations, it was not successfully deliv-
ered to all such patients.21 Patients with borderline
resectable anatomy, or those with findings indeterminate
for distant metastases or with a marginal performance
status received neoadjuvant therapy off protocol.17
Neoadjuvant chemotherapy and/or chemoradiation was
administered either at our institution or under the care of
the patient’s referring oncologist. The specific regimens
have been previously described in detail.22–24,30 Briefly,
external-beam radiotherapy usually consisted of 50.4 Gy in
28 fractions or 30 Gy in 10 fractions. Concomitant che-
motherapy consisted of 5-fluorouracil, paclitaxel,
gemcitabine, or capecitabine at radiosensitizing doses.
Chemotherapy, when delivered alone (usually before che-
moradiation in the later part of the study period examined
herein), consisted of gemcitabine alone or in combination.
Approximately 4 to 6 weeks after the completion of all
neoadjuvant treatment, patients underwent restaging eval-
uation that included CT and a complete physiologic
assessment to determine their suitability for operation.
Patients without evidence of progressive disease and who
could safely undergo major abdominal surgery in the
opinion of the operating surgeon and the multidisciplinary
treatment group were brought to the operating room for
planned resection of the primary tumor.
Pancreatic resection was performed in a standard fash-
ion, as previously described.31,32 Tangential or segmental
resection of the superior mesenteric vein, portal vein, or
SMPV confluence was performed when the operating sur-
geon could not separate the pancreatic head or the uncinate
process from these vessels without leaving gross tumor on
the vessel or risking uncontrolled venotomy. When limited
involvement of the common hepatic artery was identified,
segmental resection of this vessel was performed with
primary anastomosis or interposition grafting.
Histopathologic Evaluation of Surgical Specimens
For the purposes of this report, the original pathology
report of each patient was rereviewed in detail. When
available, the original histopathology slides of all patients
who survived at least 5 years were rereviewed by a single
faculty gastrointestinal pathologist (H.W.) to confirm the
diagnosis. Pretreatment cytologic or histologic biopsy
samples from patients who were reported to have experi-
enced a complete response to neoadjuvant therapy were
also rereviewed.
Since July 1990, a standardized system for the patho-
logic evaluation of PD specimens has been used at our
institution. This system enabled prospective evaluation of
the status of the SMA margin of resection. The technique
for assessment of the SMA margin was the same regardless
of whether vascular resection was performed. Early in our
institutional experience, the SMA margin was evaluated by
microscopic examination of an en face section.33 Begin-
ning in January 2000, the SMA margin was evaluated
according to the American Joint Commission on Cancer
(AJCC) Cancer Staging Manual (6th edition) guidelines.34
Margins were designated R0 if no tumor cells were iden-
tified at all of the resection margins. The designation R1
was applied if tumor cells were present at the SMA margin
or at the final common bile/hepatic duct or pancreatic
transection margin (these later two margins were often
resected again in the event of a positive frozen-section
diagnosis). Tumor size was calculated by the pathologist by
measuring the maximum gross transverse diameter of the
tumor after resection. This measurement was difficult to
determine in some patients after preoperative therapy
because the tumor was often hard to distinguish from
uninvolved adjacent pancreatic parenchyma by gross
examination. Although histopathologic grade was recorded
for each cancer, this pathologic factor was not included in
the univariate or multivariate analyses because of the rel-
atively subjective nature of the assessment of tumor grade.
Follow-Up and Statistical Analysis
After completion of all treatment, patients were evalu-
ated every 3–4 months by physical examination, chest
radiography, and abdominal CT scan. In patients without
evidence of disease after 2 years of follow-up, evaluations
were reduced to 6-month intervals. All but five patients
evaluated during the time period under study had a mini-
mum of 5 years of follow-up unless they died within
5 years of their date of diagnosis. The remaining five
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patients (detailed below) were foreign and were lost to
follow-up within 5 years from diagnosis. These five
patients were excluded from the analysis.
The development of a new low-density mass in the
region of the resected pancreas or root of mesentery was
considered evidence of local recurrence, even in the
absence of symptoms or biopsy confirmation. Radiographic
evidence of a new low-density mass in the liver or lungs
was typically considered evidence for distant recurrence.
Peritoneal recurrence was defined as the development of
new ascites on physical examination or CT. When radio-
graphic findings were consistent with recurrent cancer,
biopsy was rarely performed except in patients with late
recurrence of disease ([5 years), particularly when first
identified in the lung; in these patients, biopsy was often
performed to rule out a second primary lung cancer. Only
the first site or sites of recurrent disease was documented.
Patients who died after a confirmed recurrence were
assumed to have died of PC (DWD) unless otherwise
noted. Patients who died without recurrence were consid-
ered to have died of another cause (DOC), either if another
cause was documented or if another cause was not docu-
mented but the patient had been found on serial evaluation
to have no evidence of disease (NED) within 3 months of
death. Patients in whom cause of death was not recorded
and in whom time of death from last clinical follow-up
exceeded 3 months were classified as having died of
unknown cause. Patients alive at the last evaluation were
classified either as NED or as alive with disease (AWD) if
recurrence was previously documented.
All follow-up was measured from the date of histopath-
ologic diagnosis. Overall survival was calculated by the date
of death or last contact. Disease-specific survival was cal-
culated by the date of death with disease; patients who died of
another or unknown cause were censored. The Kaplan-Meier
method was used to generate survival curves by clinical
characteristics. Multiviariate logistic regression analysis was
conducted to identify factors associated with overall survival
of C5 years. Variables that were significant on univariate
analysis at P B .25 were included in the multivariate analysis.
All statistical tests were two tailed, with a significance level
of P \ .05. SPSS software version 15.0 (SPSS, Chicago, IL)
was used for all statistical analyses.
RESULTS
Between 1990 and 2002, a total of 2,217 patients with
biopsy-confirmed PC were evaluated at our institution.
Among these, the initial radiographic evaluation revealed
locally advanced or metastatic disease in 610 and 992
patients, respectively. Of the remainder, 337 (15% of 2,217
total patients) ultimately underwent surgical resection for a
resectable or borderline resectable primary PC. Follow-up
for survival was complete for a minimum of 5 years or to
the date of death (if death occurred before 5 years) in 332
(99%) of the 337 patients. The remaining five patients were
lost to follow-up at a median of 9.8 months from diagnosis
and were excluded from analysis. Each of these five
patients came from outside the United States and had
tumors of the pancreatic head or uncinate process. None
had previously been administered chemotherapy or che-
moradiation; three had undergone prior laparotomy with an
unsuccessful attempt at tumor resection. At referral, one
patient underwent an R0 PD and was found to have dis-
ease-negative lymph nodes. The remaining four patients
received neoadjuvant treatment before PD: three under-
went an R0 resection and had negative lymph nodes, one
had a positive SMA margin, and four had positive regional
lymph nodes. One of the five patients lost to follow-up
required vascular resection at the time of PD.
Of the 332 patients whom we could evaluate, 91 (27%)
survived at least 5 years, and 241 (73%) patients died within
5 years of diagnosis. Original histopathology slides of the
tumors from 86 of the 91 patients who survived 5 years were
available for repeat review. Pathology repeat review led to a
change in the diagnosis of four (5%) patients, including a
change to adenocarcinoma arising in the distal common bile
duct in two patients, adenocarcinoma arising within an
intraductal papillary mucinous neoplasm in one patient, and
a mixed adenocarcinoma/neuroendocrine carcinoma in one
patient. This last patient was left in the study population, and
the other three patients were excluded from further analysis.
The original diagnosis of PC of ductal origin was confirmed
in the remaining 82 patients (of 86 with available slides).
After excluding 3 of the 4 patients in whom the diagnosis
was changed, the final study population included 329
patients: 88 (27%) who survived 5 years (83 of whom
underwent pathology repeat review), and 241 (73%) who did
not survive 5 years. Systemic chemotherapy and/or che-
moradiation had been administered to 21 patients (6%)
before referral, and 48 patients (15%) had undergone prior
laparotomy with an unsuccessful attempt at tumor resection.
Demographic and treatment factors are listed in Table 1.
Univariate analysis revealed no difference between cohorts
of patients who did and did not survive 5 years in terms of
sex, age, type of operation performed and the need for
vascular resection, operative blood loss, length of hospital
stay, use of neoadjuvant or adjuvant therapy, or tumor size.
However, patients who survived 5 years were less likely to
have undergone attempted tumor resection before referral
and were more likely to have undergone a margin-negative
(R0) resection and to have disease-negative lymph nodes.
Surgical margins were grossly negative in all patients; 52
(16%) of 329 total patients were found to have microscop-
ically positive (R1) margins in the final pathology report.
Multidisciplinary Management of Pancreatic Cancer 839
TABLE 1 Univariate analysis
of demographic and treatment-
related factors for the 329
consecutive patients who were
evaluated for pancreatic
adenocarcinoma between 1990
and 2002 and underwent
resection
P comparison between survival
cohorts
a Ratio of the number of
positive lymph nodes to the
number examined
b Adenocarcinoma identified in
6 of 12 nodes in one patient and
1 of 2 in the other
CHA common hepatic artery
Clinical factor Total Survival
\5 years
Survival
C5 years
P value
Patients (n) 329 241 88
Demographics
Sex, n (%) .34
Male 190 (58) 143 (59) 47 (53)
Female 139 (42) 98 (41) 41 (47)
Age (years) .70
Median (mean) 64 (63) 64 (63) 63 (62)
Range 30–85 39–82 30–85
Surgery
Type of operation, n (%) .26
Pancreaticoduodenectomy 302 (92) 219 (91) 83 (94)
Distal pancreatectomy 20 (6) 15 (6) 5 (6)
Total pancreatectomy 7 (2) 7 (3) 0 (0)
Reoperative, n (%) 48 (15) 43 (18) 5 (6) .006
Vascular resection, n (%) 108 (33) 83 (34) 25 (28) .30
Superior mesenteric or portal vein 101 (31) 76 (32) 25 (28)
CHA 9 (3) 7 (3) 2 (2)
Inferior vena cava 4 (1) 4 (2) 0 (0)
Operative blood loss (ml) .08
Median (mean) 950 (1289) 1000 (1374) 900 (1057)
Range 100–18,000 100–18,000 125–3600
Length of stay (days) .14
Median (mean) 12 (15) 13 (15) 11 (13)
Range 5–108 5–108 6–41
Additional therapy
Neoadjuvant treatment, n (%) 253 (77) 188 (78) 65 (74) .43
Chemotherapy 36 (11) 27 (11) 9 (10)
Chemoradiation 248 (76) 185 (77) 63 (72)
Adjuvant treatment, n (%) 59 (18) 42 (18) 17 (20) .68
Chemotherapy 19 (6) 15 (6) 4 (5)
Chemoradiation 49 (15) 34 (14) 15 (17)
Surgery alone, n (%) 25 (8) 18 (7) 7 (8) .95
Tumor histopathology
Tumor size (cm) .09
Median (mean) 3.0 (3.0) 3.0 (3.1) 3.0 (2.8)
Range .2–13 .2–13 .3–8.0
Margin status, n (%) .04
R0 277 (84) 197 (82) 80 (91)
R1 52 (16) 44 (18) 8 (9)
Lymph node status, n (%) .01
N0 172 (52) 116 (48) 56 (64)
N1 157 (48) 125 (52) 32 (36)
Lymph node ratio, n (%)a .05
0 171 (52) 115 (48) 56 (64)
0–.2 93 (28) 72 (30) 21 (24)
.2–.4 44 (13) 35 (15) 9 (10)
[.4 20 (6) 18 (7) 2 (2)b
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Among 49 R1 PDs, microscopically positive margins
included the SMA margin (n = 44), the final pancreatic
transection margin (n = 10) and the final common bile/
hepatic duct margin (n = 2). In addition, one patient who
underwent total pancreatectomy had a microscopically
positive SMA margin, and two patients who underwent
distal pancreatectomy had a microscopically positive pan-
creatic transection margin. The median number of lymph
nodes examined in the pathology specimen was 15 (range,
0–48). In patients with node-positive disease, the median
number of positive lymph nodes was 2 (range, 1–21).
Importantly, only 25 (8%) of the 329 patients underwent
surgery alone without any form of additional therapy; 301
(91%) received either preoperative or postoperative che-
motherapy or chemoradiation. In three patients who did not
receive neoadjuvant therapy, the administration of postop-
erative therapy could neither be confirmed nor excluded.
Survival
The median overall survival of the 329 patients was
23.9 months (95% confidence interval [95% CI] 20.89,
26.9). Eighty-eight patients survived 5 years from diag-
nosis for an actual 5-year survival rate of 27% (Fig. 1a). At
last follow-up, 275 (84%) of 329 patients had died,
including 4 (1%) who died in the perioperative period. The
median follow-up for the 54 patients who were still alive at
last follow-up was 7.6 years (range, 5.0–16.1 years).
The 88 patients who survived 5 years or longer had a
median overall survival of 11.3 years. At last follow-up, 34
of these 5-year survivors had died and 54 remained alive.
Of the 34 patients who had died, 17 were classified as
DWD and 11 were classified as DOC and had no evidence
of PC at the time of death. Six patients died of unknown
cause. Of the 54 patients who were alive at last follow-up,
51 were NED and 3 were AWD. The 241 patients who did
not survive 5 years included the 4 perioperative deaths, 208
patients DWD, 19 DOC, and 10 in whom the exact cause of
death could not be determined. The disease-specific sur-
vival for the entire population was 26.5 months (95% CI
23.1, 29.9) (Fig. 1b).
Of the 329 total patients in this analysis, 145 patients
treated between 1990 and 1998 had a potential of 10 years of
follow-up. Among these, 20 patients survived 10 years,
yielding a 10-year actual survival rate of 14%. At last contact,
10 of the 20 patients were NED, 7 were DOC, and in 3, the
exact cause of death could not be determined; these 3 patients
were last documented NED at 10.3 years, 11.1 years, and
11.6 years after diagnosis. No 10-year survivor died with
documented recurrent PC at the time of death.
Treatment and histopathologic clinical factors were com-
pared between patients who did and did not survive 5 years by
a multivariate logistic regression model constructed from
variables that were significant on univariate analysis at P B
.25 (Table 2). By use of this model, we found that negative
lymph nodes (odds ratio 1.92, 95% CI 1.13, 3.27, P = .02)
and lack of a history of prior attempt at resection (odds ratio
4.05, 95% CI 1.97, 11.94, P = .01) were statistically signif-
icant prognostic factors associated with 5-year survival.
Disease Recurrence
Recurrent PC was documented in 229 (70%) of the 329
patients at 244 sites of first recurrence (Fig. 2). Of these 229
patients, 225 were DWD and 3 were AWD at last contact.
One additional patient experienced recurrence but was
classified as DOC at the time of death; this patient developed
histopathologically confirmed metastatic PC isolated to the
left frontal lobe of the brain 21 months after diagnosis,
underwent craniotomy and metastasectomy, and ultimately
FIG. 1 (a) Actual overall and (b) disease-specific survival of patients with resectable or borderline resectable pancreatic adenocarcinoma who
were evaluated at M. D. Anderson Cancer Center between 1990 and 2002 and who underwent resection
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died 9.5 years after her original diagnosis. Cause of death
was renal failure unrelated to her cancer. All confirmed cases
of recurrence occurred within 6.7 years of diagnosis and 211
(92%) of the 229 patients who experienced recurrence did so
within the first 3 years after diagnosis. Death with disease
occurred at a median of 5.6 months after the date of first
recurrence (range, .1–57.1 months) in the 225 patients who
died with documented recurrent PC.
Among the 229 patients whose disease recurred, the
most common sites of first recurrence were liver (n = 107;
47%), lung (n = 50; 22%), tumor bed and regional lymph
nodes (n = 39; 17%), and peritoneum (n = 30; 13%)
(Fig. 2). Recurrence within the first 3 years of diagnosis
most commonly manifested as hepatic metastasis: 104
(46%) of 226 sites of first recurrence within the first
3 years of diagnosis versus 3 (17%) of 18 sites of first
recurrence after 3 years from diagnosis. In contrast,
recurrent disease identified after the third year was most
common in the lungs: 10 (56%) of 18 sites of first recur-
rence after the third year versus 40 (18%) of 226 sites of
first recurrence within the first 3 years.
Among the 88 patients who survived 5 years, 21 patients
experienced recurrence (Table 3). Within the first 5 years
of diagnosis, 14 (67%) of 21 patients recurred at 15 sites:
liver (n = 3; 21%), lung (n = 7; 50%), tumor bed or
regional lymph nodes (n = 2; 14%), and other sites
(n = 3; 21%). After 5 years of follow-up, we documented
an additional seven patients with first sites of recurrent PC
in the lung (n = 6; 86%), peritoneum (n = 1; 14%), or
dermis (n = 1; 14%). For each of these late recurrences, a
tissue biopsy was performed to exclude a second primary
cancer. In total, of 21 patients whose disease recurred and
who survived 5 years, only 3 (14%) experienced recur-
rence recurred in the liver and only 2 (10%) experienced
local recurrence. Most first recurrences in the 21 patients
who survived 5 years were located in the lung (n = 13;
62%), particularly when the recurrence developed late. In
contrast, of the 208 patients who experienced recurrence
and who did not survive 5 years, recurrences occurred in
the liver (n = 104; 50%), tumor bed and regional lymph
nodes (n = 38; 18%), lung (n = 37; 18%), and peritoneum
(n = 28; 14%) (Table 4).
DISCUSSION
Of 329 consecutive patients who underwent surgical
resection of their primary PC, 88 (27%) survived 5 years,
which to our knowledge is the highest actual survival rate
reported (Table 5). We attribute this result to the use of
objective criteria for the selection of patients for surgery, a
standardized approach to the technical aspects of the
operation (to minimize local recurrence), an institutional
emphasis on multimodality therapy, and the frequent use of
neoadjuvant treatment sequencing, which may result in
avoiding surgery in patients most susceptible to early dis-
ease recurrence. However, it is important to note that
patients included in this report were treated between 1990
and 2002 to allow for a minimum follow-up of 5 years;
patients treated more recently may do even better with the
progress (albeit modest) that has resulted from the
TABLE 2 Multivariate analysis of clinicopathologic factors associ-
ated with 5-year survival
Prognostic variable No. of
patients
Odds
ratio
95% CI P value
No prior attempt at resection 281 4.05 1.97, 11.94 .01
Lymph nodes negative (N0) 157 1.92 1.13, 3.27 .02
R0 resection 277 1.96 .86, 4.45 .11
Factors included in the multivariate model included those significant
on univariate analysis at P B .25: tumor size, length of stay, previous
attempt at tumor resection, R status, nodal status, and EBL estimated
blood loss
95% CI 95% confidence interval
80
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FIG. 2 Frequency, location, and timing
of disease recurrence after resection for
patients with resectable and borderline
resectable pancreatic adenocarcinoma
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development and use of systemic chemotherapy and the
integration of systemic therapy, chemoradiation, and sur-
gery into contemporary treatment schemas.
The selection of patients for surgery was influenced by
the use of high-quality pretreatment cross-sectional imag-
ing with CT, treatment sequencing that often involved
neoadjuvant therapy, and the clinical assessment of patients
by experienced oncology specialists. We used objective
CT-based criteria to define the extent of disease as
resectable, borderline resectable, locally advanced, or
metastatic.29 Importantly, local tumor resectability was
determined preoperatively, and surgery was considered
only in patients with resectable or borderline resectable
disease. In the absence of extrapancreatic metastatic dis-
ease, an aggressive approach was taken to venous resection
and reconstruction when isolated venous involvement was
the only impediment to an otherwise complete gross
resection.18 In contrast, we did not attempt resection in
TABLE 3 Timing and first site
or sites of recurrent disease in
21 five-year survivors whose
disease recurred
DWD dead with disease, DOC
dead of other cause, AWD alive
with disease
a Histopathologically verified
Patient No. Site of first
recurrence
Time to
recurrence
(months)
Recurrence to
last follow-up
(months)
Overall survival
(months)
Current
status
1 Lunga 10 54 64 DWD
2 Liver 12 56 68 DWD
3 Locoregionala 13 47 60 DWD
4 Lunga 16 57 73 DWD
5 Braina 21 114 135 DOC
6 Abdominal walla 25 41 66 AWD
7 Liver, lung 29 37 66 DWD
8 Livera 42 23 65 DWD
9 Locoregionala 43 27 69 DWD
10 Lunga 47 23 70 AWD
11 Lunga 49 20 69 DWD
12 Lunga 57 9 65 AWD
13 Lung 57 3 60 DWD
14 Peritoneuma 58 7 65 DWD
15 Lunga 70 15 85 DWD
16 Lunga 71 1 71 DWD
17 Dermisa 71 1 73 DWD
18 Lunga 76 12 88 DWD
19 Lunga 78 12 91 DWD
20 Lung,a Peritoneum 80 4 83 DWD
21 Lunga 80 11 91 DWD
TABLE 4 Comparison of sites
of first recurrence between 5-
year survivors and patients who
did not survive 5 years
a Totals may exceed 100% as a
result of multiple sites of first
recurrence in several patients
Characteristic Survival
\5 years
(n = 241)
Survival C5 years (n = 88)
n n Recurrence
\5 years (n)
Recurrence
C5 years (n)
No. of patients whose disease recurred 208 21 14 7
Site of first recurrencea
Liver 104 (50) 3 (14) 3 (21) 0
Lung 37 (18) 13 (62) 7 (50) 6 (86)
Locoregional 38 (18) 2 (10) 2 (14) 0
Peritoneum 28 (13) 2 (10) 1 (7) 1 (14)
Abdominal wall/dermis 1 (1) 2 (10) 1 (7) 1 (14)
Brain 0 1 (5) 1 (7) 0
Bone 3 (1) 0 0 0
Other 6 (3) 0 0 0
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patients with locally advanced, stage III disease in whom a
gross (R0 or R1) resection was not possible. In patients
who undergo an incomplete gross (R2) resection, length of
survival is not improved in comparison to cases of stage III
disease managed without surgery in patients who receive
chemotherapy and/or chemoradiation.35 Indeed, among
patients with advanced disease8–11,13 and among those who
underwent a grossly incomplete (R2) resection11,13 who
were explicitly included in prior reports of long-term sur-
vival after pancreatic resection, only a single 5-year
survivor (reported to have had stage III disease) was
identified.8 Accurate pretreatment staging and multidisci-
plinary consensus with regard to resectability (based on CT
images) is something that can—and should—be performed
at all medical centers that offer surgical treatment for PC.36
Such a practice will minimize the inappropriate use of
surgery in patients with advanced disease and will ensure
that all patients with resectable disease are considered for
surgery, we hope as part of a multimodality treatment
program.
Consensus is growing that chemotherapy with or without
radiotherapy combined with surgery results in higher rates
of survival in patients with resectable PC than surgery
alone.2,3,15,37–39 In this report, 91% of patients received
either neoadjuvant or adjuvant therapy, and most patients
were enrolled onto a clinical trial. Importantly, neoadjuvant
therapy was delivered to 77% of all patients. The cytotoxic
effect of such induction therapy is likely responsible for the
lower-than-expected rates of microscopically involved
lymph nodes and positive resection margins observed in the
surgical specimens.30,40 The administration of chemother-
apy and/or chemoradiation before surgery also enriches the
population of patients selected to undergo pancreatic
resection with those most likely to have a favorable out-
come compared with patients treated with surgery first. In
our most recent two clinical trials of neoadjuvant therapy
for patients with stage I and II PC, 30% of patients who
began neoadjuvant therapy did not undergo PD as a result of
disease progression, evolving medical comorbidities, or a
decline in performance status.26,27 These patients, who had
a median survival of \12 months, include those patients
who would not have received a survival benefit from sur-
gery as a result of the presence of metastatic disease that
was radiographically occult at the time of pretreatment
staging, and those with medical comorbidities that were
also not readily apparent at the time of diagnosis. Neoad-
juvant treatment sequencing accurately identified those
patients who would otherwise have experienced early
postoperative recurrence and those who may have an
increased risk for perioperative complications; such patients
did not undergo pancreatectomy. Surgery-last treatment
sequencing benefits both the patients who undergo resection
of their primary tumor and those who do not.
We recently reported our institutional experience with
patients having borderline resectable pancreatic cancer, a
prospectively identified subset of AJCC stage III disease, in
whom a neoadjuvant strategy is particularly important.17,29
At our institution, three clearly defined groups of patients
were classified as borderline resectable: (1) patients with
strictly defined borderline resectable local tumor anatomy,
predominantly arterial abutment, as described above; (2)
patients with localized tumors who also had additional CT
findings suspicious but indeterminate for metastatic dis-
ease; and (3) patients with a marginal but potentially
recoverable performance status or extensive comorbidities
requiring a prolonged evaluation that precluded immediate
major abdominal surgery. In each of these three groups, we
took advantage of the theoretical benefits of neoadjuvant
treatment sequencing over a long time period (minimum of
4 months) of systemic chemotherapy and chemoradiation.
TABLE 5 International series of long-term survivors after treatment for pancreatic adenocarcinoma
Series No. of
patients
PD
(%)
Stages
included
Adjuvant
treatment
(%)
R0
(%)
R1/R2
(%)
N1
(%)
Vascular
resection
(%)
Median
OS (Mo)
Actual 5-year
survivors,
n (rate %)
MDACC (current study) 329 92 PR, BR 91 84 16/0 48 33 24 88 (27)
Mayo Clinic13 357 100 PR, LA, M 77 77 18/5 49 13 17 62 (17)
Johns Hopkins12 564 100 NR NR NR NR NR NR NR 96 (17)
Memorial Sloan-Kettering
Cancer Center9
618 85 PR, M 21 73 27/0 NR 0 NR 75 (12)
University of Indiana11 226 90 PR, LA 34 70 28/2 56 6 13 9 (4)
Seoul National University, Korea10 123 81 PR, LA, M 49 76 24a 54 14 15 11 (9)
Mount Sinai Hospital, Toronto8 123 91 PR, LA 21 NR 15b 43 10 14 18 (15)
PD pancreaticoduodenectomy, PR potentially resectable, BR borderline resectable, LA locally advanced, M metastatic, NR not reported, OS
overall survival, N1 positive regional lymphadenopathy
a No distinction made between R1 and R2 resections
b No distinction made between R1 and R2 resections; number of R0 resections not stated
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Serial restaging evaluations at 2-month intervals selected
patients for additional therapy and ultimately surgery; only
patients with an acceptable performance status and no
evidence of disease progression at the end of neoadjuvant
therapy underwent surgery.
In our previously published series of 160 patients treated
with this approach, 41% of patients completed all therapy,
including surgery; 56% of resected specimens had a path-
ologic response to treatment characterized by\50% tumor
viability, and 94% of resections resulted in microscopically
negative (R0) margins. The 41% of patients who completed
all therapy including surgery had a median survival of
40 months. Median survival was 13 months for the 59% of
patients who developed disease progression or evolving
medical comorbidities. Patients with borderline resectable
disease are at high risk for having CT-occult distant
metastases, likely are at higher risk for a positive resection
margin than patients with stage I or II PC, and often require
a larger, more complex, and higher-risk operation to
remove their primary tumor. When the magnitude of the
operation and the risk for recurrence are both increased,
neoadjuvant treatment sequencing becomes more attractive
as a strategy to more precisely select patients who will
benefit from pancreatectomy.
Patients who did not receive neoadjuvant therapy were
routinely encouraged to receive postoperative adjuvant
therapy, either, typically as part of a clinical trial. However,
a number of factors may delay or prohibit the administration
of adjuvant therapy in the postoperative patient. Indeed, a
recent investigation of national practice patterns for mul-
timodality therapy use reported that\50% of patients who
underwent pancreatectomy at high-volume centers received
chemotherapy or chemoradiation, although the reasons for
the low rate of multimodality therapy were unclear.15 These
data are supported by two recently published large single-
institution experiences in which adjuvant therapy was
received by only 44% and 60% of eligible patients who had
received a surgery-first treatment strategy for PC.41,42 In a
previous study from our institution, we reported that 26% of
patients who underwent PD without any prior treatment did
not receive intended adjuvant therapy.21 Patients did not
receive postoperative adjuvant therapy for reasons that
could be classified into three categories: treatment related
(surgical complications, delayed recovery), disease related
(disease progression), and patient related (advanced age,
marginal preoperative performance status, medical comor-
bidities, patient refusal). For those patients with an Eastern
Cooperative Oncology Group (ECOG) performance status
that we would consider of marginal acceptance for major
surgery (in the lower range of ECOG 2), a surgery-first
strategy is likely to be associated with both an increased risk
for complications and a high likelihood of not receiving any
additional oncologic treatment. An understanding of the
complexity of delivering multimodality therapy to patients
of advanced age who require a large cancer operation and
often have marked medical comorbidities will become even
more important as our systemic therapies for PC improve.
The present report failed to reveal an association
between the administration of neoadjuvant or adjuvant
therapy and long-term survival. However, this is not sur-
prising, given the high rate of combined modality treatment
among all patients, the relatively modest patient numbers,
and the retrospective design of this study. Only 7% of
patients did not receive systemic therapy and/or chemora-
diation in addition to surgery.
The frequent use of neoadjuvant therapy and the stan-
dardized approach to surgery likely influenced the low rate
of margin positivity (16%). In a previous report from our
institution focusing specifically on the incidence of R1
resections and the implications of this pathologic finding,
the frequency of a positive SMA margin was less in those
patients who received preoperative chemoradiation (13%)
compared with those patients taken directly to surgery
(19%).19 This difference was not statistically significant
but was clinically important, given the selection bias in
favor of going straight to surgery, without neoadjuvant
therapy, in patients with smaller tumors whose theoretical
risk for an R1 resection was thought to be low. In fact, such
carefully selected patients actually had a higher frequency
of having a disease-positive SMA margin on final patho-
logic analysis of the PD specimen. This finding lends
further support to the observation that PC can extend along
visceral perineural fibers to the SMA and a positive
microscopic margin can be found when the grossly visible
tumor seems to be separate from the lateral wall of the
SMA. Both multimodality therapy and proper surgical
technique may be necessary to minimize the risk for a
positive SMA margin and thereby reduce the risk of local
recurrence. For example, all tissue to the right of the SMA
should be removed with the PD specimen; the application
of a stapling devise or a series of clamps without visible
identification of the SMA should be avoided. In this report,
local recurrence was seen radiographically in 42 (13%) of
the 329 patients. Local control is clearly necessary (but not
sufficient) for long-term survival, and as our systemic
therapies improve, the importance of maximizing local
disease control at the time of initial treatment may provide
further enthusiasm for neoadjuvant chemoradiation.
In this report, factors adversely associated with long-
term survival on multivariate analysis included the pres-
ence of metastatic disease in regional lymph nodes and a
previous attempt at tumor resection before referral to our
institution. Of the 88 five-year survivors, only five patients
had undergone an unsuccessful attempt at tumor removal
before referral. However, 48 patients had undergone lapa-
rotomy for planned pancreatectomy before referral; the
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effect of an unsuccessful prereferral laparotomy was pro-
found and something not widely discussed in the literature.
The importance of carefully selecting patients for PC sur-
gery who are compatible with the skill set of the surgeon
cannot be overstated.
Of the 88 five-year survivors, 32 (36%) were found to
have pathologically involved lymph nodes. In fact, of the
157 node-positive patients, 32 (20%) survived 5 years. To
what degree the favorable outcome in patients with N1
disease is related to the use of multimodality therapy
cannot be accurately determined. One would assume that
the selection bias introduced by neoadjuvant treatment
sequencing combined with the frequent use of systemic
chemotherapy is partly responsible for this encouraging
result. In any event, the finding that 20% of node-positive
patients were alive at 5 years after diagnosis would argue
against routine lymph node biopsy at the time of surgery
because node-positive disease does not seem to represent a
contraindication to surgical resection of the primary tumor
when performed as part of a multimodal treatment strategy.
Finally, the incidence and pattern of disease recurrence
warrants further comment. As demonstrated in Fig. 2, most
recurrences occurred early and developed in the abdomen
(largely in the liver). In contrast, late recurrences devel-
oped predominantly in the lung. This pattern of recurrence
supports the use of abdominal CT or magnetic resonance
imaging for routine follow-up, particularly within the first 3
to 5 years after definitive treatment. Although not analyzed
in this report, we found that serum levels of CA 19-9 are
frequently also helpful, unless undetectable (indicative of
individuals with the Lewis a–b blood group antigen who do
not synthesize CA 19-9). In this report, the latest cancer
recurrence was identified 6.7 years from diagnosis, and the
latest cancer-related death occurred at 7.6 years. These
findings support prior observations that 5-year survival
does not always equate with cure for patients with this
disease.9,13 However, the plateau of our disease-specific
survival curve (Fig. 1b) does suggest that patients free of
disease at 7 to 8 years after diagnosis are at very low risk
for death from recurrent PC. For patients who died of
recurrent disease within 5 years, death occurred at a
median of 5.5 months (range, .1–36.5 months) after
recurrence was identified. In contrast, of the 17 five-year
survivors who died of recurrent PC, death occurred at a
median of 15 months (range, .7–51 months) after the
diagnosis of recurrence (Table 3). These data suggest that
5-year survivors who are not cured are characterized by an
as-yet undefined tumor biology that includes a predispo-
sition for pulmonary metastases and a more indolent form
of disease progression.
In conclusion, we report a consecutive series of patients
with resectable (stage I, II) and borderline resectable (stage
III) PC who were treated with curative intent to include
surgical resection of the primary tumor. The favorable
long-term survival reported herein reflects what is possible
when a well-selected group of patients are carefully staged
with high-quality imaging and treated in a disease site-
specific multidisciplinary program with state-of-the-art
surgery, combination chemotherapy, and radiotherapy.
Future progress in the treatment of patients with PC will
emphasize both the optimization of our current technolo-
gies and treatments, as well as the development of novel
and more effective systemic therapies.
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